CMPX vs. PCB, TCBX, PROK, RGNX, HLVX, ITOS, TSHA, VALN, EXAI, and KYTX
Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include PCB Bancorp (PCB), Third Coast Bancshares (TCBX), ProKidney (PROK), REGENXBIO (RGNX), HilleVax (HLVX), iTeos Therapeutics (ITOS), Taysha Gene Therapies (TSHA), Valneva (VALN), Exscientia (EXAI), and Kyverna Therapeutics (KYTX).
PCB Bancorp (NASDAQ:PCB) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership, community ranking and profitability.
In the previous week, PCB Bancorp had 3 more articles in the media than Compass Therapeutics. MarketBeat recorded 7 mentions for PCB Bancorp and 4 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 0.89 beat PCB Bancorp's score of 0.89 indicating that PCB Bancorp is being referred to more favorably in the media.
PCB Bancorp has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.
PCB Bancorp has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than PCB Bancorp, indicating that it is currently the more affordable of the two stocks.
33.0% of PCB Bancorp shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 25.0% of PCB Bancorp shares are held by insiders. Comparatively, 30.0% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
PCB Bancorp has a net margin of 14.69% compared to PCB Bancorp's net margin of 0.00%. Compass Therapeutics' return on equity of 9.09% beat PCB Bancorp's return on equity.
PCB Bancorp currently has a consensus target price of $17.00, indicating a potential upside of 11.70%. Compass Therapeutics has a consensus target price of $9.00, indicating a potential upside of 538.30%. Given PCB Bancorp's stronger consensus rating and higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than PCB Bancorp.
Compass Therapeutics received 12 more outperform votes than PCB Bancorp when rated by MarketBeat users. Likewise, 72.73% of users gave Compass Therapeutics an outperform vote while only 48.00% of users gave PCB Bancorp an outperform vote.
Summary
PCB Bancorp beats Compass Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Compass Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Compass Therapeutics Competitors List
Related Companies and Tools
